Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors
Authors
Keywords
Cushing’s disease, Atypical tumor, Pasireotide, Paradoxical response, Pituitary carcinoma
Journal
Pituitary
Volume 19, Issue 6, Pages 605-611
Publisher
Springer Nature
Online
2016-09-17
DOI
10.1007/s11102-016-0755-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Single-Center 10-Year Experience with Pasireotide in Cushing’s Disease: Patients’ Characteristics and Outcome
- (2016) L. Trementino et al. HORMONE AND METABOLIC RESEARCH
- The Treatment of Cushing's Disease
- (2015) Rosario Pivonello et al. ENDOCRINE REVIEWS
- Clinical, biochemical and imaging characteristics of Cushing's macroadenomas and their long-term treatment outcome
- (2014) Harshal Ramesh Kakade et al. CLINICAL ENDOCRINOLOGY
- Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures
- (2014) A. Mohamed et al. ENDOCRINE-RELATED CANCER
- Effective Long-Term Treatment of Cushing's Disease with Pasireotide: A Case Report
- (2013) Lin Lu et al. Endocrine Practice
- Sustained Improvements in Plasma ACTH and Clinical Status in a Patient With Nelson's Syndrome Treated With Pasireotide LAR, a Multireceptor Somatostatin Analog
- (2013) Laurence Katznelson JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phosphorylation of Threonine 333 Regulates Trafficking of the Human sst5Somatostatin Receptor
- (2013) Aline Petrich et al. MOLECULAR ENDOCRINOLOGY
- Stimulatory effect of SOM230 on human and rat adrenal corticosteroid secretion in vitro
- (2012) F. Pecori Giraldi et al. GENERAL AND COMPARATIVE ENDOCRINOLOGY
- A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
- (2012) Annamaria Colao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review
- (2012) Ilan Shimon et al. Pituitary
- SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases
- (2010) H. Bode et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Differential Ligand-Mediated Pituitary Somatostatin Receptor Subtype Signaling: Implications for Corticotroph Tumor Therapy
- (2009) Anat Ben-Shlomo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways
- (2009) Renzo Cescato et al. MOLECULAR ENDOCRINOLOGY
- Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Traffickingin Vitro
- (2008) Sarah Lesche et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started